Buda Juice stock jumped 7.9% to US$8.93, yet the earnings story is less euphoric than the chart suggests. The market is cheering strong Q2 revenue of US$4.5m and solid net income of US$0.47m. The emotional bid is growth. The hard question is margin pressure.

Over the past year Buda Juice has moved from rich profitability to a slimmer 17.1% net margin, while the stock trades on a P/E of 46.5x. Today looks more like investors paying up for the revenue trajectory than a cool assessment of earnings quality and valuation strain.

Is Buda Juice trading at a justified growth premium, or has the market pushed NYSEAM:BUDA into stretched territory on thin margins and non cash earnings? Compare the DCF and P/E signals side by side in our valuation…